- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06877793
Diagnóstico en tiempo real de infecciones necrotizantes de tejidos blandos (NSTI) en tiempo real utilizando modelado cinético verde de indocianina (ICG)
Necrotizing soft-tissue infections (NSTIs, a.k.a. "necrotizing fasciitis" or "flesh-eating bacteria") are aggressive infections that can progress rapidly from mild symptoms to sepsis, multi-organ failure, and death. NSTI cases present with non-specific clinical, imaging, and laboratory findings, and standard-of-care techniques for NSTI diagnosis lack sensitivity and specificity, resulting in frequent misdiagnosis and delayed care, which is the single most important predictor of survival. Consequently, the cumulative mortality rate for patients with NSTIs is 20- 30%; a dire need exists for more accurate and rapid detection of NSTIs. Fluorescence-guided surgery is a nascent technology seeking to improve the recognition of anatomical structures and disease processes using fluorescent probes (fluorophores). Indocyanine green (ICG) is an FDA-approved, near-infrared fluorophore with a >60-year safety record for vascular perfusion assessment. A distinguishing histological feature of NSTIs is prominent blood vessel thrombosis in affected tissues. Leveraging these pro-thrombotic effects, our study group has demonstrated in a first-in-human study (NCT04839302) that intravenous administration of ICG and immediate fluorescence imaging reveals prominent signal deficits in NSTI-positive tissues that differentiate significantly with increased signal seen with more common-and less virulent-infections such as cellulitis. We seek now to evaluate this imaging technique on a broader scale and determine if our findings are consistent for patients affected by NSTI-causing pathogens that are not endemic to our region. This prospective, observational, multicenter clinical study will involve video-rate ICG fluorescence imaging of patients suspected of having NSTIs who present to eight tertiary, Level 1 medical centers across the United States (Aim 1). Using dynamic contrast-enhanced fluorescence imaging (DCE-FI), time profiles of ICG fluorescence intensity from different tissue pixels/regions will be extracted and parameterized to extract first-pass kinetic features. These DCE-FI features, which characterize tissue perfusion, will be evaluated alone and in combination with anonymized electronic medical record data to create a DCE-FI-based clinical decision tool and a machine- learning-based fusion (DCE FI+lab/imaging data) tool; these will be compared to identify the most accurate means of diagnosing NSTIs (Aim 2). The best-performing tool will then be evaluated-compared to current diagnostic tests-in a prospective observational clinical study of patients presenting to tertiary emergency departments with findings concerning for NSTIs (Aim 3). Based on our human study, fluorescence imaging will not delay current standard of care. To ensure data fidelity, all sites will use similar: 1) commercial fluorescence imaging systems and accessories; and 2) validated commercial fluorescence reference phantoms. Based on our early results, we have strong confidence that following rigorous testing, ICG DCE-FI will lead to an entirely new methodology for rapid identification of patients with NSTIs, which will ultimately reduce patient morbidity and improve survival.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Eric R Henderson, MD
- Número de teléfono: 603-650-5133
- Correo electrónico: Eric.R.Henderson@hitchcock.org
Copia de seguridad de contactos de estudio
- Nombre: Morgan T Mazanec, MPH
- Número de teléfono: 603-308-9233
- Correo electrónico: Morgan.T.Mazanec@Hitchcock.ORG
Ubicaciones de estudio
-
-
California
-
Los Angeles, California, Estados Unidos, 90095
- Reclutamiento
- University of California, Los Angeles
-
Investigador principal:
- Christopher Lee, MD
-
Contacto:
- Christopher Lee, MD
- Número de teléfono: 310-319-1234
- Correo electrónico: ChristopherLee@mednet.ucla.edu
-
Sub-Investigador:
- Nicholas Bernthal, MD
-
Stanford, California, Estados Unidos, 94305
- Reclutamiento
- Stanford University
-
Investigador principal:
- Joseph Forrester, MD
-
Contacto:
- Joseph Forrester, MD
- Correo electrónico: jdf1@stanford.edu
-
Sub-Investigador:
- Ariel Knight, MD
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Reclutamiento
- Emory University/Grady Memorial Hospital
-
Contacto:
- Morgan Fuller
- Número de teléfono: (404) 251-8953
- Correo electrónico: jaimo.ahn@emory.edu
-
Investigador principal:
- Jaimo Ahn, MD, PhD
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48104
- Reclutamiento
- University of Michigan
-
Contacto:
- Molly Hunter, MD
- Correo electrónico: huntmary@med.umich.edu
-
Investigador principal:
- Molly Hunter, MD
-
Investigador principal:
- Raymond Jean, MD
-
-
New Hampshire
-
Lebanon, New Hampshire, Estados Unidos, 03756
- Reclutamiento
- Dartmouth-Hitchcock Medical Center
-
Contacto:
- Eric R Henderson, MD
- Número de teléfono: 603-650-5133
- Correo electrónico: Eric.R.Henderson@hitchcock.org
-
Sub-Investigador:
- Jonathan Elliot, PhD
-
Sub-Investigador:
- Samuel S Streeter, PhD
-
Sub-Investigador:
- Macgregor Montano, PharmD
-
Sub-Investigador:
- Scott Rodi, MD
-
Investigador principal:
- Eric R Henderson, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Reclutamiento
- University of Pennsylvania
-
Contacto:
- Niels Martin, MD, PhD
- Correo electrónico: Niels.Martin@pennmedicine.upenn.edu
-
Investigador principal:
- Niels Martin, MD, PhD
-
Sub-Investigador:
- Sunil Singhal, MD, PhD
-
Sub-Investigador:
- Jane Keating, MD
-
Pittsburgh, Pennsylvania, Estados Unidos, 15213
- Reclutamiento
- University of Pittsburgh Medical Center
-
Contacto:
- Kurt Weiss, MD
- Número de teléfono: (412) 802-4137
- Correo electrónico: weiskr@UPMC.EDU
-
Investigador principal:
- Kurt Weiss, MD
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37235
- Reclutamiento
- Vanderbilt University
-
Contacto:
- Jonathan Schoenecker, MD, PhD
- Número de teléfono: (615) 936-3391
- Correo electrónico: jon.schoenecker@vumc.org
-
Investigador principal:
- Jonathan Schoenecker, MD, PhD
-
Sub-Investigador:
- William Obremskey, MD
-
Sub-Investigador:
- Eben Rosenthal, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Patients presenting to the ED or clinic who are considered at intermediate- or high-risk for NSTI.
Descripción
Inclusion Criteria:
- Age ≥18 years.
- Clinical suspicion of NSTI based on the local standard of care warranting:
- Hospital admission for observation due to suspected NSTI; and/or
- Soft tissue biopsy to rule in/out suspected NSTI; and/or
- Surgical debridement for suspected NSTI; and/or
- Specific institutional threshold criteria for triggering NSTI work-up; and
- Ability to give written informed consent.
Exclusion Criteria:
- History of allergy to ICG and/or iodine.
- Pregnant women or nursing mothers.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Determine if tissue perfusion, determined by first-pass ICG fluorescence kinetics, is reliably reduced in the setting of a necrotizing infection compared to a non-necrotizing infection.
Periodo de tiempo: From enrollment to the end of fluorescence imaging (about 1 day)
|
We will evaluate first-pass fluorescence signal intensity changes from indocyanine green (ICG), a vascular perfusion fluorophore, in the setting of severe soft-tissue infections to determine if ICG fluorescence may be an accurate and reliable diagnostic test for differentiating life-threatening necrotizing infections from non-life-threatening non-necrotizing infections. |
From enrollment to the end of fluorescence imaging (about 1 day)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Determine if first-pass ICG fluorescence kinetics in patients with necrotizing infections vary based on the causative bacterial species.
Periodo de tiempo: From enrollment to the end of imaging and lab results (about 30 days)
|
In patients who had a documented necrotizing soft-tissue infection, we will compare first-pass fluorescence signal intensity changes from ICG based on the predominant causative bacterial species isolated from a patient's infection to determine if ICG signal changes vary by species. |
From enrollment to the end of imaging and lab results (about 30 days)
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 02002719
- 1R01AI184513-01 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Data will only be shared in aggregate.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .